Incremental Weight Loss Improves Cardiometabolic Risk in Extremely Obese Adults - 29/09/11
, Meghan M. Brashear, MPH, Alok K. Gupta, MD, Jennifer C. Rood, PhD, Donna H. Ryan, MDAbstract |
Objective |
Excessively obese adults often acquire many metabolic disorders that put them at high risk for developing type 2 diabetes mellitus and cardiovascular disease. We investigated the hypothesis that cardiometabolic risk in a primary care cohort of 208 excessively obese adults (body mass index 40-60 kg/m2, 48 with type 2 diabetes mellitus) would deteriorate with additional weight gain and improve incrementally beginning with 5% weight reduction.
Methods |
Further analysis of the Louisiana Obese Subjects Study of excessively obese patients enrolled and followed during 2005-2008 is reported.
Results |
Weight loss correlated significantly with improvements in fasting plasma glucose, triglycerides, high- and low-density lipoprotein cholesterol, uric acid, alanine aminotransferase, lactate dehydrogenase, and high-sensitivity C-reactive protein. Most parameters deteriorated with weight gain and progressively improved with 5% or more weight loss. Except for low-density lipoprotein cholesterol, all risk factors significantly improved with≥20% loss of body weight. Among patients who had not been diagnosed with type 2 diabetes mellitus and had normoglycemia at baseline, median fasting plasma glucose increased significantly (13%) with stable or gained weight at 1 year, but did not change significantly with reduced weight. Although glucose levels did not change significantly in patients with type 2 diabetes mellitus who gained weight, a decline beginning after 5% weight reduction culminated in 25% glucose reduction with≥20% weight loss. Resting blood pressure declined independently of weight change.
Conclusion |
Very obese adults can improve their cardiometabolic risk under primary care weight management. Incremental success may help motivate further therapeutic weight reduction.
Le texte complet de cet article est disponible en PDF.Keywords : Cardiometabolic benefits of weight reduction, Diabetes, Pragmatic weight loss for class III obesity
Plan
| Funding: The Louisiana Obese Subjects Study was funded by the Office of Group Benefits, the health insurance provider for Louisiana state employees. Some of the sibutramine used in the Louisiana Obese Subjects Study was donated by Abbott Laboratories (Columbus, OH). |
|
| Conflict of Interest: None of the authors have any conflicts of interest associated with the work presented in this manuscript. |
|
| Authorship: All authors had access to the data and played a role in writing this manuscript. |
|
| Trial registration: ClinicalTrials.gov NCT00115063. |
Vol 124 - N° 10
P. 931-938 - octobre 2011 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
